KR20210152372A - Adipocyte differentiation inhibitor and composition comprising the same - Google Patents
Adipocyte differentiation inhibitor and composition comprising the same Download PDFInfo
- Publication number
- KR20210152372A KR20210152372A KR1020210035662A KR20210035662A KR20210152372A KR 20210152372 A KR20210152372 A KR 20210152372A KR 1020210035662 A KR1020210035662 A KR 1020210035662A KR 20210035662 A KR20210035662 A KR 20210035662A KR 20210152372 A KR20210152372 A KR 20210152372A
- Authority
- KR
- South Korea
- Prior art keywords
- adipocyte differentiation
- extract
- weight
- differentiation inhibitor
- parts
- Prior art date
Links
- 210000001789 adipocyte Anatomy 0.000 title claims abstract description 98
- 230000004069 differentiation Effects 0.000 title claims abstract description 88
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 239000003112 inhibitor Substances 0.000 title claims abstract description 61
- 239000000284 extract Substances 0.000 claims abstract description 92
- 239000002537 cosmetic Substances 0.000 claims abstract description 40
- 244000019459 Cynara cardunculus Species 0.000 claims abstract description 30
- 235000019106 Cynara scolymus Nutrition 0.000 claims abstract description 30
- 235000016520 artichoke thistle Nutrition 0.000 claims abstract description 30
- 235000013305 food Nutrition 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims description 21
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 235000019693 cherries Nutrition 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- QUAPPCXFYKSDSV-LBPRGKRZSA-N (2s)-5,7-dihydroxy-6-methoxy-2-phenyl-2,3-dihydrochromen-4-one Chemical compound C1([C@H]2OC3=CC(O)=C(C(=C3C(=O)C2)O)OC)=CC=CC=C1 QUAPPCXFYKSDSV-LBPRGKRZSA-N 0.000 claims description 8
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 8
- 241000574138 Ozothamnus diosmifolius Species 0.000 claims description 8
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 8
- 229960001948 caffeine Drugs 0.000 claims description 8
- ZFKKRRMUPBBYRS-UHFFFAOYSA-N norwogonin Chemical compound OC=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 ZFKKRRMUPBBYRS-UHFFFAOYSA-N 0.000 claims description 8
- 235000013399 edible fruits Nutrition 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- GPDJGLOROGNHJD-UHFFFAOYSA-N 5,6,7-trihydroxy-2-phenyl-2,3-dihydrochromen-4-one Chemical compound C1C(=O)C=2C(O)=C(O)C(O)=CC=2OC1C1=CC=CC=C1 GPDJGLOROGNHJD-UHFFFAOYSA-N 0.000 claims description 6
- 240000004731 Acer pseudoplatanus Species 0.000 claims description 6
- 235000002754 Acer pseudoplatanus Nutrition 0.000 claims description 6
- 239000009429 Ginkgo biloba extract Substances 0.000 claims description 6
- 235000006485 Platanus occidentalis Nutrition 0.000 claims description 6
- LKOJGSWUMISDOF-UHFFFAOYSA-N oroxylin A Chemical compound C=1C(=O)C2=C(O)C(OC)=C(O)C=C2OC=1C1=CC=CC=C1 LKOJGSWUMISDOF-UHFFFAOYSA-N 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 claims description 3
- KIHKKNWFLFSAHD-YXXBAVPESA-N CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O Chemical compound CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O KIHKKNWFLFSAHD-YXXBAVPESA-N 0.000 claims description 3
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 claims description 3
- BJBKXYIIWYIZCX-UHFFFAOYSA-N Trigraecum Natural products C1=C(O)C(OC)=CC(C(C=2)=O)=C1OC=2C1=CC=CC=C1 BJBKXYIIWYIZCX-UHFFFAOYSA-N 0.000 claims description 3
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical group O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 claims description 3
- 229940015301 baicalein Drugs 0.000 claims description 3
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 claims description 3
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 claims description 3
- 229960003321 baicalin Drugs 0.000 claims description 3
- 239000004474 valine Substances 0.000 claims description 3
- 241000167854 Bourreria succulenta Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 238000004519 manufacturing process Methods 0.000 abstract description 13
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- 238000000605 extraction Methods 0.000 description 23
- 238000002360 preparation method Methods 0.000 description 15
- 230000011759 adipose tissue development Effects 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 12
- 230000004130 lipolysis Effects 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 10
- 239000008213 purified water Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- 241001290151 Prunus avium subsp. avium Species 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 208000008589 Obesity Diseases 0.000 description 7
- 235000020824 obesity Nutrition 0.000 description 7
- 208000035484 Cellulite Diseases 0.000 description 6
- 206010049752 Peau d'orange Diseases 0.000 description 6
- 230000036232 cellulite Effects 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000010931 gold Substances 0.000 description 6
- 229910052737 gold Inorganic materials 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 230000002366 lipolytic effect Effects 0.000 description 6
- 210000000229 preadipocyte Anatomy 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 238000004925 denaturation Methods 0.000 description 5
- 230000036425 denaturation Effects 0.000 description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 210000000689 upper leg Anatomy 0.000 description 5
- KRZBCHWVBQOTNZ-RDJMKVHDSA-N (3r,5r)-3,5-bis[[(e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-1,4-dihydroxycyclohexane-1-carboxylic acid Chemical compound O([C@@H]1CC(O)(C[C@H](C1O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 KRZBCHWVBQOTNZ-RDJMKVHDSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- KRZBCHWVBQOTNZ-WXAIXHMISA-N 3,5-di-O-caffeoylquinic acid Natural products O[C@@H]1[C@H](C[C@](O)(C[C@@H]1OC(=O)C=Cc2ccc(O)c(O)c2)C(=O)O)OC(=O)C=Cc3ccc(O)c(O)c3 KRZBCHWVBQOTNZ-WXAIXHMISA-N 0.000 description 4
- FKIYLTVJPDLUDL-ZWUNSDNISA-N Apigenin 7-O-rutinoside Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4ccc(O)cc4)Oc3c2)O1)[C@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 FKIYLTVJPDLUDL-ZWUNSDNISA-N 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 4
- FKIYLTVJPDLUDL-SLNHTJRHSA-N Isorhoifolin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C=C3C(C(C=C(O3)C=3C=CC(O)=CC=3)=O)=C(O)C=2)O1 FKIYLTVJPDLUDL-SLNHTJRHSA-N 0.000 description 4
- FKIYLTVJPDLUDL-FLPYCHHVSA-N Isorhoifolin Natural products C[C@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3cc(O)c4C(=O)C=C(Oc4c3)c5ccc(O)cc5)[C@H](O)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H](O)[C@@H]1O FKIYLTVJPDLUDL-FLPYCHHVSA-N 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 102100031786 Adiponectin Human genes 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108010016731 PPAR gamma Proteins 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000007443 liposuction Methods 0.000 description 3
- PEFNSGRTCBGNAN-QNDFHXLGSA-N luteolin 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 PEFNSGRTCBGNAN-QNDFHXLGSA-N 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- -1 polyethylene Polymers 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- YDDUMTOHNYZQPO-UHFFFAOYSA-N 1,3-bis{[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}-4,5-dihydroxycyclohexanecarboxylic acid Natural products OC1C(O)CC(C(O)=O)(OC(=O)C=CC=2C=C(O)C(O)=CC=2)CC1OC(=O)C=CC1=CC=C(O)C(O)=C1 YDDUMTOHNYZQPO-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- SITQVDJAXQSXSA-CEZRHVESSA-N Cynarin Natural products O[C@@H]1C[C@@](C[C@H](O)[C@H]1OC(=O)C=Cc2ccc(O)c(O)c2)(OC(=O)C=Cc3cccc(O)c3O)C(=O)O SITQVDJAXQSXSA-CEZRHVESSA-N 0.000 description 2
- YDDUMTOHNYZQPO-RVXRWRFUSA-N Cynarine Chemical group O([C@@H]1C[C@@](C[C@H]([C@@H]1O)O)(OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDUMTOHNYZQPO-RVXRWRFUSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 101000775469 Homo sapiens Adiponectin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 102000000536 PPAR gamma Human genes 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- YDDUMTOHNYZQPO-BKUKFAEQSA-N cynarine Natural products O[C@H]1C[C@@](C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)(OC(=O)C=Cc3ccc(O)c(O)c3)C(=O)O YDDUMTOHNYZQPO-BKUKFAEQSA-N 0.000 description 2
- 229950009125 cynarine Drugs 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229930005346 hydroxycinnamic acid Natural products 0.000 description 2
- 235000010359 hydroxycinnamic acids Nutrition 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000004132 lipogenesis Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- PEFNSGRTCBGNAN-UHFFFAOYSA-N nephrocizin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 PEFNSGRTCBGNAN-UHFFFAOYSA-N 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000004003 subcutaneous fat Anatomy 0.000 description 2
- NGSWKAQJJWESNS-ZZXKWVIFSA-N trans-4-coumaric acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 235000003840 Amygdalus nana Nutrition 0.000 description 1
- 101100248253 Arabidopsis thaliana RH40 gene Proteins 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100102503 Caenorhabditis elegans ver-3 gene Proteins 0.000 description 1
- 241000132536 Cirsium Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 241000220299 Prunus Species 0.000 description 1
- 235000011432 Prunus Nutrition 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- 108010013296 Sericins Proteins 0.000 description 1
- 206010040102 Seroma Diseases 0.000 description 1
- 206010040893 Skin necrosis Diseases 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- HIMJIPRMECETLJ-UHFFFAOYSA-N Wogonin Natural products COc1cc(O)c(O)c2C(=O)C=C(Oc12)c3ccccc3 HIMJIPRMECETLJ-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000579 abdominal fat Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229930193997 cynaroside Natural products 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000013538 functional additive Substances 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- 229940106580 ginkgo biloba leaf extract Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 150000002343 gold Chemical class 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000012623 in vivo measurement Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000010363 phase shift Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000014774 prunus Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- XLTFNNCXVBYBSX-UHFFFAOYSA-N wogonin Chemical compound COC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=CC=C1 XLTFNNCXVBYBSX-UHFFFAOYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9771—Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 지방세포의 분화를 억제하고 지방의 생성을 감소시킬 수 있는 지방세포 분화 억제제 및 이를 포함함으로써 피하 지방 분해 효과를 안전하면서도 저비용으로 얻을 수 있는 화장료 조성물 또는 식품 조성물에 관한 것이다.The present invention relates to an adipocyte differentiation inhibitor capable of inhibiting the differentiation of adipocytes and reducing the production of fat, and a cosmetic or food composition that can safely and inexpensively obtain the effect of subcutaneous fat decomposition by including the adipocyte differentiation inhibitor.
인간의 지방세포는 중성지방의 형태로 여분의 에너지를 저장하며 필요할 때마다 저장된 에너지를 지방산의 형태로 분비한다. 여기서 비만은 지방산(지방조직)이 과잉으로 축적된 상태로, 영양 섭취량이 많고 주로 앉아서 생활하며 유전적으로 비만해질 가능성이 있는 사람은 지방산이 증가하면서 심각한 건강 문제를 일으키게 된다.Human fat cells store extra energy in the form of triglycerides and release the stored energy in the form of fatty acids whenever needed. Here, obesity is a state in which fatty acids (adipose tissue) accumulate excessively, and people who have a high nutritional intake and live mostly sedentary life are genetically likely to become obese, causing serious health problems as fatty acids increase.
상기 비만 중 국소 비만은 복부, 둔대퇴부 등의 특정 부위에 과도하게 지방이 침착된 것으로, 내분비적, 해부학적 요인에 의해 여성에게 더욱 흔하게 나타난다. 이러한 국소 비만은 건강과 삶의 질에 직접적인 영향을 주고, 미용 및 성형 측면에서도 개인의 심리적 위축과 사회적 부적응을 초래할 수 있다. 이에 건강 및 미적 관점에서 비만을 개선하기 위한 방법이 다각적인 측면에서 이루어지고 있다.Among the obesity, local obesity is excessive fat deposition in specific areas, such as the abdomen and gluteal region, and is more common in women due to endocrine and anatomical factors. Such local obesity has a direct impact on health and quality of life, and may lead to psychological atrophy and social maladaptation of individuals in terms of beauty and plastic surgery. Accordingly, methods for improving obesity from a health and aesthetic point of view are being made in various aspects.
상기 비만의 해소를 위해 복부 지방 등의 국소 지방을 제거할 수 있는 지방흡입술(liposuction)이 이루어진 바 있다. 이러한 지방흡입술은 영구적으로 상태를 유지할 수 있으며 비교적 손쉽고 빠르게 가시적인 효과를 볼 수 있다는 장점이 있지만, 부위에 따라 전신 및 국소 마취가 필요하며, 시술 도중 근육, 혈관, 림프관에 손상을 주는 단점이 있고, 이로 인하여 윤곽 불균형(contour irregularity), 장액종(seroma), 과다색소침착(hyperpigmentation), 비대칭(asymmetry), 비후성 반흔 (hypertrophic scar), 피부괴사(skin necrosis), 감염(infection) 등을 동반하는 심각한 부작용이 일어나는 문제점이 있다.Liposuction, which can remove local fat such as abdominal fat, has been made in order to relieve the obesity. Such liposuction has the advantage of being able to maintain the condition permanently and seeing a visible effect relatively easily and quickly, but it requires general and local anesthesia depending on the site, and has the disadvantage of damaging muscles, blood vessels, and lymphatic vessels during the procedure. , resulting in contour irregularity, seroma, hyperpigmentation, asymmetry, hypertrophic scar, skin necrosis, infection, etc. There is a problem that serious side effects occur.
이에 따라 지방흡입술의 심각한 부작용을 보완하기 위해 비수술적 요법이 등장한 바 있다. 상기 비수술적 요법으로는 지방 용해 작용이 있는 물질을 피하에 주사하는 지방 분해 주사가 보편적이며, 이외에 식이요법, 약물요법 등이 있다. 그러나 상기 비수술적 요법으로는 비만을 완전히 해결할 수 없으며, 안전성에 대한 보장이 없고 요요 현상 등의 부작용이 나타나고 있다.Accordingly, non-surgical therapies have emerged to compensate for the serious side effects of liposuction. As the non-surgical therapy, lipolytic injection, which is a subcutaneous injection of a substance having a lipolytic action, is common, and in addition, there are dietary therapy, drug therapy, and the like. However, the non-surgical therapy cannot completely solve obesity, there is no guarantee of safety, and side effects such as yo-yo phenomenon appear.
이에 안전하면서 저비용으로 지방의 생성을 감소시킬 수 있는 기술이 요구되고 있는 실정이다.Accordingly, there is a need for a technology capable of reducing the production of fat at a low cost while being safe.
본 발명은 지방세포의 분화를 억제하고 지방의 생성을 감소시킬 수 있는 지방세포 분화 억제제를 제공하고자 한다.An object of the present invention is to provide an adipocyte differentiation inhibitor capable of inhibiting the differentiation of adipocytes and reducing the production of adipocytes.
또한 본 발명은 상기 지방세포 분화 억제제를 포함하는 화장료 조성물을 제공하고자 한다.Another object of the present invention is to provide a cosmetic composition comprising the adipocyte differentiation inhibitor.
또 본 발명은 상기 지방세포 분화 억제제를 포함하는 식품 조성물을 제공하고자 한다.Another object of the present invention is to provide a food composition comprising the adipocyte differentiation inhibitor.
상기 과제를 해결하기 위해 본 발명은, 황금추출물; 및 아티초크잎추출물을 포함하는 지방세포 분화 억제제를 제공한다.The present invention in order to solve the above problems, gold extract; And it provides an adipocyte differentiation inhibitor comprising an artichoke leaf extract.
상기 황금추출물은 바이칼레인(Baicalein), 바이칼린(Baicalin), 디하이드로바이칼레인(Dihydrobaicalein), 오록실린 A(Oroxylin A), 디하이드로오록실린 A(Dihydrooroxylin A), 오고닌(Wogonin) 및 노르오고닌(Norwogonin)으로 이루어진 군에서 선택되는 1종 이상을 포함할 수 있다.The golden extract is baicalein, baicalin, dihydrobaicalein, oroxylin A, dihydrooroxylin A, ogonin and norogo It may include one or more selected from the group consisting of nin (Norwogonin).
상기 아티초크잎추출물은 시너린(Cynarine), 시나로사이드(Cynaroside), 하이드록시시남산(Hydroxycinnamic acid), 3,5-디-O-카페오일퀸산(3,5-di-O-caffeoylquinic acid) 및 아피제닌-7-루티노시드(apigenin-7-rutinoside)로 이루어진 군에서 선택되는 1종 이상을 포함할 수 있다.The artichoke leaf extract is cynarine, cinaroside, hydroxycinnamic acid, 3,5-di-O-caffeoylquinic acid (3,5-di-O-caffeoylquinic acid) ) and apigenin-7-rutinoside (apigenin-7-rutinoside) may include one or more selected from the group consisting of.
상기 황금추출물과 상기 아티초크잎추출물의 혼합비율은 1:1 내지 5:1의 중량비일 수 있다.The mixing ratio of the golden extract and the artichoke leaf extract may be a weight ratio of 1:1 to 5:1.
이러한 지방세포 분화 억제제는 카페인, 펩타이드 및 은행나무잎추출물로 이루어진 군에서 선택되는 1종 이상을 더 포함할 수 있다.The adipocyte differentiation inhibitor may further include at least one selected from the group consisting of caffeine, peptides and ginkgo leaf extract.
상기 펩타이드는 Valine-Histidine-Valine-Valine(VHVV), Isoleucine-Leucine-Leucine(ILL) 및 Leucine-Leucine-Leucine(LLL)로 표시되는 펩타이드로 이루어진 군에서 선택되는 1종 이상일 수 있다.The peptide may be at least one selected from the group consisting of peptides represented by Valine-Histidine-Valine-Valine (VHVV), Isoleucine-Leucine-Leucine (ILL), and Leucine-Leucine-Leucine (LLL).
한편 본 발명은, 상기 지방세포 분화 억제제; 및 스피큘을 포함하는 화장료 조성물을 제공한다.On the other hand, the present invention, the adipocyte differentiation inhibitor; And it provides a cosmetic composition comprising a spicule.
상기 스피큘은 가수분해 단백질 또는 친수성 물질로 코팅된 것일 수 있다.The spicule may be coated with a hydrolyzed protein or a hydrophilic material.
이러한 화장료 조성물은 백미꽃추출물, 회화나무열매추출물 및 세룰라타벚나무꽃추출물로 이루어진 군에서 선택되는 1종 이상을 더 포함할 수 있다.Such a cosmetic composition may further include one or more selected from the group consisting of white rice flower extract, sycamore tree fruit extract, and cerulata cherry tree flower extract.
다른 한편 본 발명은, 상기 지방세포 분화 억제제를 포함하는 식품 조성물을 제공한다.On the other hand, the present invention provides a food composition comprising the adipocyte differentiation inhibitor.
본 발명에 따른 화장료 조성물 및/또는 식품 조성물은 천연물에서 유래된 복합 추출물 성분을 함유하는 지방세포 분화 억제제를 포함하기 때문에 인체에 안전하며, 저비용으로 지방 생성 감소 또는 지방 분해의 효과를 얻을 수 있다.The cosmetic composition and/or food composition according to the present invention is safe for the human body because it contains an adipocyte differentiation inhibitor containing a complex extract component derived from a natural product, and can achieve the effect of reducing lipogenesis or decomposing fat at low cost.
도 1은 본 발명에 따른 지방세포 분화 억제제에 포함되는 황금추출물의 지방세포 분화 억제 및 지방 생성 감소 여부에 대한 평가 결과를 나타낸 것이다.
도 2는 본 발명에 따른 지방세포 분화 억제제에 포함되는 아티초크잎추출물의 지방세포 분화 억제 및 지방 생성 감소 여부에 대한 평가 결과를 나타낸 것이다.
도 3 내지 도 8은 본 발명에 따른 실험예 3 내지 실험예 8에서 얻어진 평가 결과를 나타낸 것이다.1 shows the evaluation results of whether the golden extract contained in the adipocyte differentiation inhibitor according to the present invention inhibits adipocyte differentiation and reduces adipogenesis.
2 shows the evaluation results of whether the artichoke leaf extract contained in the adipocyte differentiation inhibitor according to the present invention inhibits adipocyte differentiation and reduces adipogenesis.
3 to 8 show evaluation results obtained in Experimental Examples 3 to 8 according to the present invention.
본 발명의 설명 및 청구범위에서 사용된 용어나 단어는, 통상적이거나 사전적인 의미로 한정해서 해석되어서는 아니되며, 발명자는 그 자신의 발명을 가장 최선의 방법으로 설명하기 위해 용어의 개념을 적절하게 정의할 수 있다는 원칙에 입각하여, 본 발명의 기술적 사상에 부합하는 의미와 개념으로 해석되어야만 한다.The terms or words used in the description and claims of the present invention should not be construed as being limited to their ordinary or dictionary meanings, and the inventor must properly understand the concept of the term in order to best describe his invention. Based on the principle that can be defined, it should be interpreted as meaning and concept consistent with the technical idea of the present invention.
본 발명은 천연 성분에서 유래된 복합 추출물을 통해 지방세포 분화 억제 및 지방생성 감소(지방분해) 효과를 얻을 수 있도록 한 지방세포 분화 억제제 및 이를 포함하는 화장료 조성물에 관한 것으로, 이에 대해 구체적으로 설명하면 다음과 같다.The present invention relates to an adipocyte differentiation inhibitor and a cosmetic composition comprising the same, in which adipocyte differentiation inhibition and adipogenesis reduction (lipolysis) effects can be obtained through a complex extract derived from natural ingredients. As follows.
여기서 본 발명에서의 추출물은 원료의 추출 과정을 거쳐 얻어진 추출물, 얻어진 추출물을 분획한 분획물, 얻어진 추출물을 여과한 여과물, 얻어진 추출물을 감압 농축한 농축물 등을 포함하는 개념일 수 있다.또한 상기 추출물을 제조하는 방법은 유효성분의 추출 정도나 보존 정도를 고려하여 열수 추출법, 침지 추출법, 수증기 증류법, 냉침 추출법, 환류 냉각 추출법, 초음파 추출법, 초임계 추출법, 아임계 추출법, 용매 추출법, 용출법, 압착법, 고온 추출법, 또는 고압 추출법 등이 적용될 수 있다.Here, the extract in the present invention may be a concept including an extract obtained through a raw material extraction process, a fraction obtained by fractionating the obtained extract, a filtrate obtained by filtering the obtained extract, and a concentrate obtained by concentrating the obtained extract under reduced pressure. In consideration of the degree of extraction or preservation of the active ingredient, hot water extraction method, immersion extraction method, steam distillation method, cold extraction method, reflux cooling extraction method, ultrasonic extraction method, supercritical extraction method, subcritical extraction method, solvent extraction method, elution method, A compression method, a high temperature extraction method, or a high pressure extraction method may be applied.
본 발명에 따른 지방세포 분화 억제제는 황금추출물 및 아티초크잎추출물을 포함한다.The adipocyte differentiation inhibitor according to the present invention includes a golden extract and an artichoke leaf extract.
본 발명에 따른 지방세포 분화 억제제에 포함되는 황금추출물은 황금을 세척 및 건조하고, 상술한 추출물을 제조하는 방법을 통해 얻어진 것일 수 있다. 구체적으로 용매를 이용하여 추출 과정을 거친 후, 여과 및/또는 건조시키는 과정 등을 거쳐 얻어진 것일 수 있다. 상기 추출 과정에서 사용되는 추출 용매로는 물, 메탄올, 에탄올, 에틸 아세테이트 또는 이들의 혼합물 등이 사용될 수 있다. 보다 구체적으로 상기 추출 과정은 세척 및 건조된 황금 뿌리를 70 내지 90 ℃에서 2 내지 6 시간 동안 추출 용매로 추출한 후, 여과 및 희석하는 과정을 거치는 것으로 이루어질 수 있다.The golden extract contained in the adipocyte differentiation inhibitor according to the present invention may be obtained by washing and drying gold, and preparing the extract described above. Specifically, it may be obtained through an extraction process using a solvent, followed by filtration and/or drying. As the extraction solvent used in the extraction process, water, methanol, ethanol, ethyl acetate, or a mixture thereof may be used. More specifically, the extraction process may consist of extracting washed and dried golden roots with an extraction solvent at 70 to 90° C. for 2 to 6 hours, followed by filtering and dilution.
상기 황금(Scutellaria Baicalensis)은 냄새가 거의 없고 약간 쓴맛이 나는 식물이다. 이러한 황금을 이용하여 얻어진 황금추출물은 지방이 축적되는 것을 억제하는 작용을 할 수 있는 것으로, 본 발명에 따른 지방세포 분화 억제제는 이러한 작용을 하는 황금추출물을 포함함에 따라 우수한 지방세포 분화 억제 및 지방생성 감소 효과를 얻을 수 있다.The gold (Scutellaria Baicalensis) is a plant with almost no odor and a slightly bitter taste. The golden extract obtained using this gold can act to inhibit the accumulation of fat, and the adipocyte differentiation inhibitor according to the present invention contains the golden extract having such an action, thereby providing excellent inhibition of adipocyte differentiation and adipogenesis. reduction effect can be obtained.
구체적으로 상기 황금추출물은 지방세포 분화 억제에 관여하는 화합물을 포함하는 것으로, 보다 구체적으로는 바이칼레인(Baicalein), 바이칼린(Baicalin), 디하이드로바이칼레인(Dihydrobaicalein), 오록실린 A(Oroxylin A), 디하이드로오록실린 A(Dihydrooroxylin A), 오고닌(Wogonin) 및 노르오고닌(Norwogonin)으로 이루어진 군에서 선택되는 1종 이상의 화합물을 포함하는 것일 수 있다.Specifically, the golden extract contains a compound involved in the inhibition of adipocyte differentiation, and more specifically, baicalein, baicalin, dihydrobaicalein, oroxylin A. , Dihydrooroxylin A (Dihydrooroxylin A), Ogonin (Wogonin), and may include one or more compounds selected from the group consisting of Norwogonin (Norwogonin).
상기 황금추출물의 함량은 지방세포 분화 억제, 다른 성분들과의 상호작용 등을 고려할 때, 지방세포 분화 억제제 100 중량부를 기준으로 5 내지 50 중량부, 구체적으로는 10 내지 25 중량부일 수 있다.The content of the golden extract may be 5 to 50 parts by weight, specifically 10 to 25 parts by weight, based on 100 parts by weight of the adipocyte differentiation inhibitor, considering the inhibition of adipocyte differentiation and interaction with other components.
본 발명에 따른 지방세포 분화 억제제에 포함되는 아티초크잎추출물은 아티초크잎을 세척 및 건조하고, 상술한 추출물을 제조하는 방법을 통해 얻어진 것일 수 있다. 구체적으로 용매를 이용하여 추출 과정을 거친 후, 여과 및/또는 건조시키는 과정 등을 거쳐 얻어진 것일 수 있다. 상기 추출 과정에서 사용되는 추출 용매로는 물, 메탄올, 에탄올, 에틸 아세테이트 또는 이들의 혼합물 등이 사용될 수 있다. 보다 구체적으로 상기 추출 과정은 세척 및 건조된 아티초크잎을 20 내지 30 ℃에서 20 내지 40 시간 동안 추출 용매로 추출하고, 가열 및 농축한 후, 여과 및 희석하는 과정을 거치는 것으로 이루어질 수 있다.The artichoke leaf extract contained in the adipocyte differentiation inhibitor according to the present invention may be obtained by washing and drying artichoke leaves and preparing the extract described above. Specifically, it may be obtained through an extraction process using a solvent, followed by filtration and/or drying. As the extraction solvent used in the extraction process, water, methanol, ethanol, ethyl acetate, or a mixture thereof may be used. More specifically, the extraction process may consist of extracting the washed and dried artichoke leaves with an extraction solvent at 20 to 30° C. for 20 to 40 hours, heating and concentration, and then filtering and diluting.
상기 아티초크는 바닷가 근처에서 자라며, 엉겅퀴와 비슷하게 생긴 식물이다. 이러한 아티초크의 잎을 이용하여 얻어진 아티초크잎추출물은 지방분해 작용을 할 수 있는 것으로, 본 발명에 따른 지방세포 분화 억제제는 이러한 작용을 하는 아티초크잎추출물을 포함함에 따라 우수한 지방세포 분화 억제 및 지방생성 감소 효과를 얻을 수 있다.The artichoke is a plant that grows near the beach and looks similar to a thistle. The artichoke leaf extract obtained by using the leaf of the artichoke is capable of lipolytic action, and the adipocyte differentiation inhibitor according to the present invention contains the artichoke leaf extract having this action, thereby providing excellent inhibition of adipocyte differentiation and It can have the effect of reducing fat production.
구체적으로 아티초크잎추출물은 지방분해에 관여하는 화합물을 포함하는 것으로, 보다 구체적으로는 시너린(Cynarine), 시나로사이드(Cynaroside), 하이드록시시남산(Hydroxycinnamic acid), 3,5-디-O-카페오일퀸산(3,5-di-O-caffeoylquinic acid) 및 아피제닌-7-루티노시드(apigenin-7-rutinoside)를 포함하는 것일 수 있다.Specifically, the artichoke leaf extract contains compounds involved in lipolysis, and more specifically, Cynarine, Cynaroside, Hydroxycinnamic acid, 3,5-di- O-caffeoylquinic acid (3,5-di-O-caffeoylquinic acid) and apigenin-7-rutinoside (apigenin-7-rutinoside) may be included.
상기 아티초크잎추출물의 함량은 지방세포 분화 억제, 지방분해, 다른 성분들과의 상호작용 등을 고려할 때, 지방세포 분화 억제제 100 중량부를 기준으로 5 내지 50 중량부, 구체적으로는 10 내지 25 중량부일 수 있다.The content of the artichoke leaf extract is 5 to 50 parts by weight, specifically 10 to 25 parts by weight, based on 100 parts by weight of the adipocyte differentiation inhibitor, considering the inhibition of adipocyte differentiation, lipolysis, and interaction with other components. can be negative
여기서 본 발명에 따른 지방세포 분화 억제제의 효능을 고려할 때, 지방세포 분화 억제제에 포함되는 황금추출물(a)과 아티초크잎추출물(b)의 혼합비율(a:b)은 1:1 내지 5:1의 중량비일 수 있고, 구체적으로는 1:1 내지 2:1의 중량비일 수 있다.Here, in consideration of the efficacy of the adipocyte differentiation inhibitor according to the present invention, the mixing ratio (a:b) of the golden extract (a) and the artichoke leaf extract (b) included in the adipocyte differentiation inhibitor is 1:1 to 5: It may be a weight ratio of 1, specifically, it may be a weight ratio of 1:1 to 2:1.
한편 본 발명에 따른 지방세포 분화 억제제는 그 효능을 높이기 위해 카페인, 펩타이드 및 은행나무잎추출물로 이루어진 군에서 선택되는 1종 이상을 더 포함할 수 있다.Meanwhile, the adipocyte differentiation inhibitor according to the present invention may further include at least one selected from the group consisting of caffeine, peptides and ginkgo leaf extract to increase its efficacy.
본 발명에 따른 지방세포 분화 억제제에 더 포함되는 카페인은 지방세포의 분화를 억제하는 작용과 함께, 지방 분해를 촉진하는 노르에피네프린이 분해되는 것을 억제하는 작용을 할 수 있다.Caffeine, further included in the adipocyte differentiation inhibitor according to the present invention, may act to inhibit the differentiation of adipocytes and to inhibit the decomposition of norepinephrine, which promotes fat breakdown.
상기 카페인의 함량은 지방세포 분화 억제, 지방분해, 다른 성분들과의 상호작용 등을 고려할 때, 지방세포 분화 억제제 100 중량부를 기준으로 0.5 내지 5 중량부, 구체적으로는 1 내지 2 중량부일 수 있다.The caffeine content may be 0.5 to 5 parts by weight, specifically 1 to 2 parts by weight, based on 100 parts by weight of the adipocyte differentiation inhibitor, in consideration of adipocyte differentiation inhibition, lipolysis, and interaction with other components. .
본 발명에 따른 지방세포 분화 억제제에 포함되는 펩타이드는 지방분해 작용을 하는 것으로, 구체적으로는 Valine-Histidine-Valine-Valine(VHVV), Isoleucine-Leucine-Leucine(ILL) 및 Leucine-Leucine-Leucine(LLL)로 표시되는 펩타이드로 이루어진 군에서 선택되는 1종 이상일 수 있다.The peptides included in the adipocyte differentiation inhibitor according to the present invention have a lipolytic action, specifically, Valine-Histidine-Valine-Valine (VHVV), Isoleucine-Leucine-Leucine (ILL) and Leucine-Leucine-Leucine (LLL). ) may be one or more selected from the group consisting of peptides represented by
상기 펩타이드의 함량은 지방분해, 다른 성분들과의 상호작용 등을 고려할 때, 지방세포 분화 억제제 100 중량부를 기준으로 0.5 내지 10 중량부, 구체적으로는 1 내지 5 중량부일 수 있다.The content of the peptide may be 0.5 to 10 parts by weight, specifically 1 to 5 parts by weight, based on 100 parts by weight of the adipocyte differentiation inhibitor, in consideration of lipolysis and interaction with other components.
본 발명에 따른 지방세포 분화 억제제에 더 포함되는 은행나무잎추출물은 은행나무잎을 세척 및 건조하고, 상술한 추출물을 제조하는 방법을 통해 얻어진 것일 수 있다. 구체적으로 용매를 이용하여 추출 과정을 거친 후, 여과 및/또는 건조시키는 과정 등을 거쳐 얻어진 것일 수 있다. 상기 추출 과정에서 사용되는 추출 용매로는 물, 메탄올, 에탄올, 에틸 아세테이트 또는 이들의 혼합물 등이 사용될 수 있다. 이러한 과정을 거쳐 얻어진 은행나무잎추출물은 지방분해 작용을 할 수 있다.The ginkgo leaf extract further included in the adipocyte differentiation inhibitor according to the present invention may be obtained by washing and drying ginkgo leaves and preparing the extract described above. Specifically, it may be obtained through an extraction process using a solvent, followed by filtration and/or drying. As the extraction solvent used in the extraction process, water, methanol, ethanol, ethyl acetate, or a mixture thereof may be used. The Ginkgo biloba leaf extract obtained through this process can act as a lipolytic agent.
상기 은행나무잎추출물의 함량은 지방분해, 다른 성분들과의 상호작용 등을 고려할 때, 지방세포 분화 억제제 100 중량부를 기준으로 0.1 내지 10 중량부, 구체적으로는 1 내지 5 중량부일 수 있다.The content of the ginkgo biloba extract may be 0.1 to 10 parts by weight, specifically 1 to 5 parts by weight, based on 100 parts by weight of the adipocyte differentiation inhibitor, in consideration of lipolysis and interaction with other components.
상술한 본 발명에 따른 지방세포 분화 억제제는 천연물에서 유래한 추출물을 복합적으로 포함되되, 각 성분들 간의 상호작용이 잘 이루어지는 추출물들을 포함하는 것으로, 이로 인해 본 발명은 우수한 지방세포 분화 억제 및 지방분해 효과를 나타낼 수 있다.The above-described adipocyte differentiation inhibitor according to the present invention contains extracts derived from natural products in a complex manner, and includes extracts with good interaction between each component. effect can be shown.
여기서 본 발명에 따른 지방세포 분화 억제제는 분산성 및 농도 조절 등을 위해 통상적으로 공지된 용매(예를 들어, 정제수)를 더 포함할 수 있다. 상기 용매의 함량은 특별히 한정되지 않으며, 상술한 각 성분(유효성분)의 함량이 제외된 잔량일 수 있다.Here, the adipocyte differentiation inhibitor according to the present invention may further include a commonly known solvent (eg, purified water) for dispersibility and concentration control. The content of the solvent is not particularly limited, and may be the remaining amount excluding the content of each component (active ingredient) described above.
한편 본 발명은 상술한 지방세포 분화 억제제를 포함함으로써 지방분해, 피부거칠기 개선, 셀룰라이트 개선 등의 효과를 나타낼 수 있는 화장료 조성물을 제공한다. 구체적으로 본 발명에 따른 화장료 조성물은 지방세포 분화 억제제 및 스피큘을 포함한다.Meanwhile, the present invention provides a cosmetic composition capable of exhibiting effects such as lipolysis, skin roughness improvement, and cellulite improvement by including the above-described adipocyte differentiation inhibitor. Specifically, the cosmetic composition according to the present invention includes an adipocyte differentiation inhibitor and spicule.
본 발명에 따른 화장료 조성물에 포함되는 지방세포 분화 억제제는 지방생성 조절, 지방분해, 셀룰라이트 개선 등의 기능을 화장료 조성물에 부여하는 역할을 한다. 여기서 지방세포 분화 억제제에 대한 설명은 상술한 바와 동일하므로 생략하도록 한다.The adipocyte differentiation inhibitor included in the cosmetic composition according to the present invention serves to impart functions such as regulating adipogenesis, lipolysis, and improvement of cellulite to the cosmetic composition. Here, the description of the adipocyte differentiation inhibitor is the same as described above, and thus will be omitted.
상기 지방세포 분화 억제제의 함량은 화장료 조성물의 전체적인 효능 및 제조효율 등을 고려할 때, 화장료 조성물 100 중량부를 기준으로, 0.05 내지 5 중량부, 구체적으로는 0.1 내지 2 중량부일 수 있다.The content of the adipocyte differentiation inhibitor may be 0.05 to 5 parts by weight, specifically 0.1 to 2 parts by weight, based on 100 parts by weight of the cosmetic composition, in consideration of the overall efficacy and manufacturing efficiency of the cosmetic composition.
본 발명에 따른 화장료 조성물에 포함되는 스피큘은 지방세포 분화 억제제와 더불어 화장료 조성물에 함유되는 성분들을 피부 깊숙이 침투시키는 역할을 한다. 구체적으로 스피큘은 침상의 형태(예를 들어, 바늘형, 원뿔형, 피라미드형)를 갖는 것으로, 이러한 스피큘은 피부에 홀(hole)을 형성시켜 화장료 조성물의 물리적 경피 흡수를 촉진시킬 수 있다. 또한 스피큘은 피부에 침투하여 피부에 쌓여 있는 각질을 밀어 올려 탈락시키는 기능도 수행할 수 있어 화장료 조성물에 피부 재생 기능도 부여할 수 있다.The spicule included in the cosmetic composition according to the present invention plays a role in deeply penetrating the components contained in the cosmetic composition together with the adipocyte differentiation inhibitor into the skin. Specifically, the spicule has a needle-like shape (eg, needle-shaped, conical, pyramid-shaped), and the spicule may form a hole in the skin to promote physical transdermal absorption of the cosmetic composition. In addition, the spicule can also perform a function of penetrating into the skin and pushing up the keratin accumulated on the skin to remove it, so that it can also impart a skin regeneration function to the cosmetic composition.
이러한 스피큘은 화장료 조성물에 함유된 성분들과의 결합율(포접율)을 높이기 위해 가수분해 단백질 또는 친수성 물질로 코팅된 것일 수 있다. 상기 가수분해 단백질은 구체적으로 하이드롤라이즈드 콜라겐, 하이드롤라이즈드 실크, 하이드롤라이즈드 케라틴, 하이드롤라이즈드 엘라스틴, 하이드롤라이즈드 소이 프로테인, 하이드롤라이즈드 휘트 프로테인 및 하이드롤라이즈드 세리신으로 이루어진 군에서 선택되는 1종 이상일 수 있다. 또한 상기 친수성 물질은 글리세롤, 에틸렌글리콜, 디에틸렌글리콜(DEG) 및 폴리에틸렌글리콜(PEG)로 이루어진 군에서 선택되는 1종 이상일 수 있다.The spicule may be coated with a hydrolyzed protein or a hydrophilic material in order to increase the binding rate (inclusion rate) with the components contained in the cosmetic composition. The hydrolyzed protein is specifically hydrolyzed collagen, hydrolyzed silk, hydrolyzed keratin, hydrolyzed elastin, hydrolyzed soy protein, hydrolyzed wheat protein and hydrolyzed sericin. It may be at least one selected from the group consisting of. In addition, the hydrophilic material may be at least one selected from the group consisting of glycerol, ethylene glycol, diethylene glycol (DEG) and polyethylene glycol (PEG).
상기 스피큘의 함량은 화장료 조성물의 전체적인 효능 및 제조효율 등을 고려할 때, 화장료 조성물 100 중량부를 기준으로, 0.01 내지 1 중량부, 구체적으로는 0.05 내지 0.1 중량부일 수 있다.The content of the spicule may be 0.01 to 1 part by weight, specifically 0.05 to 0.1 part by weight, based on 100 parts by weight of the cosmetic composition, in consideration of the overall efficacy and manufacturing efficiency of the cosmetic composition.
이와 같은 본 발명에 따른 화장료 조성물은 그 기능을 높이기 위해 백미꽃추출물, 회화나무열매추출물 및 세룰라타벚나무꽃추출물로 이루어진 군에서 선택되는 1종 이상을 더 포함할 수 있다. 구체적으로 상기 백미꽃추출물은 피부 탄력 개선 기능을, 상기 회화나무열매추출물은 피부 진정 기능을, 상기 셀루라타벚나무꽃추출물은 항산화 기능을 각각 화장료 조성물에 부여하는 역할을 할 수 있다.As described above, the cosmetic composition according to the present invention may further include one or more selected from the group consisting of white rice flower extract, sycamore tree fruit extract, and cerulata cherry tree flower extract in order to enhance its function. Specifically, the white rice flower extract may serve to provide a skin elasticity improvement function, the sycamore tree fruit extract to provide a skin soothing function, and the cellulata cherry tree flower extract to provide an antioxidant function to the cosmetic composition, respectively.
여기서 화장료 조성물의 전체적인 효능 및 제조효율 등을 고려할 때, 화장료 조성물 100 중량부를 기준으로 상기 백미꽃추출물의 함량은 0.1 내지 1 중량부, 구체적으로는 0.2 내지 0.5 중량부일 수 있고, 상기 회화나무열매추출물의 함량은 0.1 내지 1 중량부, 구체적으로는 0.2 내지 0.5 중량부일 수 있으며, 상기 셀루라타벚나무꽃추출물의 함량은 0.1 내지 1 중량부, 구체적으로는 0.2 내지 0.5 중량부일 수 있다.Here, in consideration of the overall efficacy and manufacturing efficiency of the cosmetic composition, the content of the white rice flower extract may be 0.1 to 1 part by weight, specifically 0.2 to 0.5 parts by weight, based on 100 parts by weight of the cosmetic composition, and the The content may be 0.1 to 1 parts by weight, specifically 0.2 to 0.5 parts by weight, and the content of the Cellulata cherry blossom extract may be 0.1 to 1 parts by weight, specifically 0.2 to 0.5 parts by weight.
이러한 본 발명에 따른 화장료 조성물은 화장료 조성물 분야에서 통상적으로 사용되는 정제수, 항산화제, 안정화제, 안료, 기능성 첨가제, 또는 향료 등을 더 포함할 수 있다. The cosmetic composition according to the present invention may further include purified water, antioxidants, stabilizers, pigments, functional additives, or fragrances commonly used in the field of cosmetic compositions.
또한 본 발명에 따른 화장료 조성물은 통상적인 제형으로 제조될 수 있다. 구체적으로 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 유탁액 파운데이션, 왁스 파운데이션, 또는 스프레이 등으로 제형화될 수 있다.In addition, the cosmetic composition according to the present invention can be prepared in a conventional formulation. Specifically, it may be formulated as a solution, suspension, emulsion, paste, gel, cream, lotion, powder, emulsion foundation, wax foundation, or spray.
다른 한편 본 발명은 상술한 지방세포 분화 억제제를 포함함으로써 지방분해, 셀룰라이트 개선 등의 효과를 나타낼 수 있는 식품 조성물을 제공한다. 구체적으로 본 발명에 따른 식품 조성물은 지방세포 분화 억제제를 포함한다.On the other hand, the present invention provides a food composition capable of exhibiting effects such as lipolysis and cellulite improvement by including the above-mentioned adipocyte differentiation inhibitor. Specifically, the food composition according to the present invention contains an adipocyte differentiation inhibitor.
본 발명에 따른 식품 조성물에 포함되는 지방세포 분화 억제제는 지방생성 조절, 지방분해, 셀룰라이트 개선 등의 기능을 식품 조성물에 부여하는 역할을 한다. 여기서 지방세포 분화 억제제에 대한 설명은 상술한 바와 동일하므로 생략하도록 한다.The adipocyte differentiation inhibitor contained in the food composition according to the present invention serves to impart functions such as lipogenesis control, lipolysis, and cellulite improvement to the food composition. Here, the description of the adipocyte differentiation inhibitor is the same as described above, and thus will be omitted.
상기 지방세포 분화 억제제의 함량은 식품 조성물의 전체적인 효능 및 제조효율 등을 고려할 때, 식품 조성물 100 중량부를 기준으로, 0.05 내지 5 중량부, 구체적으로는 0.1 내지 2 중량부일 수 있다.The content of the adipocyte differentiation inhibitor may be 0.05 to 5 parts by weight, specifically 0.1 to 2 parts by weight, based on 100 parts by weight of the food composition, in consideration of the overall efficacy and manufacturing efficiency of the food composition.
이와 같은 본 발명에 따른 식품 조성물은 그 기능을 높이기 위해 백미꽃추출물, 회화나무열매추출물 및 세룰라타벚나무꽃추출물로 이루어진 군에서 선택되는 1종 이상을 더 포함할 수 있다.As described above, the food composition according to the present invention may further include one or more selected from the group consisting of white rice flower extract, sycamore tree fruit extract, and cerulata cherry tree flower extract in order to enhance its function.
여기서 식품 조성물의 전체적인 효능 및 제조효율 등을 고려할 때, 식품 조성물 100 중량부를 기준으로 상기 백미꽃추출물의 함량은 0.1 내지 1 중량부, 구체적으로는 0.2 내지 0.5 중량부일 수 있고, 상기 회화나무열매추출물의 함량은 0.1 내지 1 중량부, 구체적으로는 0.2 내지 0.5 중량부일 수 있으며, 상기 셀루라타벚나무꽃추출물의 함량은 0.1 내지 1 중량부, 구체적으로는 0.2 내지 0.5 중량부일 수 있다.Here, when considering the overall efficacy and manufacturing efficiency of the food composition, the content of the white rice flower extract based on 100 parts by weight of the food composition may be 0.1 to 1 part by weight, specifically 0.2 to 0.5 parts by weight, and the The content may be 0.1 to 1 parts by weight, specifically 0.2 to 0.5 parts by weight, and the content of the Cellulata cherry blossom extract may be 0.1 to 1 parts by weight, specifically 0.2 to 0.5 parts by weight.
이러한 본 발명에 따른 식품 조성물은 향미제, 천연 탄수화물, 여러 가지 영양제, 광물(전해질), 풍미제, 착색제, 유기산, 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올 또는 탄산화제 등을 더 포함할 수 있다.The food composition according to the present invention further includes flavoring agents, natural carbohydrates, various nutrients, minerals (electrolytes), flavoring agents, coloring agents, organic acids, thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols or carbonating agents, etc. can do.
상기 천연 탄수화물로는 포도당, 과당, 말토스, 슈크로스, 덱스트린, 시클로덱스트린, 자일리톨, 소르비톨, 에리트리톨 등이 사용될 수 있다.As the natural carbohydrate, glucose, fructose, maltose, sucrose, dextrin, cyclodextrin, xylitol, sorbitol, erythritol, and the like may be used.
상기 향미제로는 타우마틴, 레바우디오시드 A, 글리시르히진, 사카린 및 아스파르탐 등이 사용될 수 있다.As the flavoring agent, thaumatin, rebaudioside A, glycyrrhizin, saccharin and aspartame may be used.
또한 본 발명에 따른 식품 조성물은 통상적인 제형으로 제조될 수 있다. 구체적으로 캡슐제, 정제, 분말, 액상, 환제, 페이스트상, 시럽, 겔, 젤리 등으로 제형화될 수 있다.In addition, the food composition according to the present invention can be prepared in a conventional formulation. Specifically, it may be formulated into capsules, tablets, powders, liquids, pills, pastes, syrups, gels, jellies, and the like.
이하, 실시예에 의하여 본 발명을 더욱 상세하게 설명하고자 한다. 그러나, 하기 실시예는 본 발명을 예시하기 위한 것으로 본 발명의 범주 및 기술사상 범위 내에서 다양한 변경 및 수정이 가능함은 통상의 기술자에게 있어서 명백한 것이며, 이들 만으로 본 발명의 범위가 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail by way of Examples. However, the following examples are intended to illustrate the present invention, and it is apparent to those skilled in the art that various changes and modifications can be made within the scope and spirit of the present invention, and the scope of the present invention is not limited thereto.
[준비예 1][Preparation Example 1]
건조된 황금 뿌리를 이용하여 다음의 과정을 거쳐 황금추출물을 준비하였다. 구체적으로, 건조된 황금 뿌리와 증류수를 1:10의 중량비율로 혼합한 후 공압 추출기 1K 압력, 80 ℃ 조건에서 4 시간 동안 추출을 진행하여 추출물을 얻었다. 얻어진 추출물을 400 mesh 폴리에틸렌(PE) 거름망으로 거른 후, 100 % 에탄올과 2.5:7.5의 중량비율로 혼합하여 황금추출물을 얻었다. A golden extract was prepared through the following process using dried golden roots. Specifically, the dried golden root and distilled water were mixed in a weight ratio of 1:10, followed by extraction in a pneumatic extractor 1K pressure and 80 °C conditions for 4 hours to obtain an extract. After the obtained extract was filtered through a 400 mesh polyethylene (PE) sieve, it was mixed with 100% ethanol in a weight ratio of 2.5:7.5 to obtain a golden extract.
[실험예 1] 황금추출물에 의한 지방세포 분화 억제 평가[Experimental Example 1] Evaluation of inhibition of adipocyte differentiation by gold extract
황금추출물이 지방전구세포(preadipocyte)의 지방세포(adipocyte) 분화에 영향을 주는지 확인하기 위해 생쥐 지방전구세포 3T3-L1에 각 시료를 농도별로 처리한 후 지방 생성을 측정하였으며, 그 결과를 도 1에 나타내었다. 이때, 측정 조건 및 과정은 다음과 같이 하였다.In order to check whether the golden extract affects the adipocyte differentiation of preadipocytes, each sample was treated with 3T3-L1 mouse preadipocytes by concentration, and then adipogenesis was measured, and the results are shown in FIG. 1 shown in At this time, the measurement conditions and process were as follows.
Cell culturecell culture
생쥐 배아섬유아세포(mouse embryonic fibroblast) 3T3-L1은 ATCC(American Type Culture Collection 사)로부터 구입하였다. 구입한 3T3-L1을 10 % fetal bovine serum(FBS, Gibco사), 100 U/mL 페니실린 및 100 μg/mL 스트렙토마이신이 함유된 DEEM(Hyclone 사)에서 배양하였다. 지방세포 분화를 위해 10 μg/ml insulin, 0.5 mM 3-isobutyl-1-methylxanthine, 1 μM dexamethasone을 배양 세포에 2일 동안 처리하면서 황금추출물을 농도별로 함께 처리하였다. 2일 후에 10 ug/ml insulin과 황금추출물이 첨가된 새로운 배지로 교환하여 배양하였으며, 매 2일마다 새로운 배지로 교환하였다. 모든 배양은 37 ℃에서 5 % CO2의 가습 인큐베이터에서 수행되었다.Mouse embryonic fibroblast 3T3-L1 was purchased from ATCC (American Type Culture Collection). Purchased 3T3-L1 was cultured in DEEM (Hyclone) containing 10% fetal bovine serum (FBS, Gibco), 100 U/mL penicillin, and 100 μg/mL streptomycin. For adipocyte differentiation, 10 μg/ml insulin, 0.5 mM 3-isobutyl-1-methylxanthine, and 1 μM dexamethasone were treated with cultured cells for 2 days, while golden extract was treated with each concentration. After 2 days, 10 ug/ml insulin and a new medium to which golden extract was added were exchanged for culture, and a new medium was exchanged every 2 days. All incubations were performed in a humidified incubator of 5% CO 2 at 37 °C.
Oil-red-O 염색Oil-red-O dyeing
3T3-L1의 지방세포 분화 정도는 Oil-red-O(Sigma aldrich사)로 지방을 염색하여 광학현미경으로 관찰하였고, 생성된 지방양은 Oil-red-O를 추출하여 측정함으로써 분석하였다. 구체적으로 분화된 3T3-L1 세포를 4% 포름알데하이드(Sigma aldrich사)로 20 분 동안 고정한 후, 0.2% Oil-red-O 용액으로 1시간 동안 염색하였다. 이 후 광학현미경(Nikon사, Ts2R 모델)에서 200 배 배율로 세포를 관찰하였다. 세포에 염색된 Oil-red-O는 100% 2-propanol(Sigma aldrich사)를 30분 동안 처리하여 추출한 후, 분광기(spectrometer, BioTeK사)를 이용하여 510 nm에서 흡광도를 측정하였다. The degree of adipocyte differentiation of 3T3-L1 was observed under a light microscope by staining fat with Oil-red-O (Sigma Aldrich), and the amount of fat produced was analyzed by extracting and measuring Oil-red-O. Specifically, the differentiated 3T3-L1 cells were fixed with 4% formaldehyde (Sigma Aldrich) for 20 minutes, and then stained with 0.2% Oil-red-O solution for 1 hour. Thereafter, cells were observed under a light microscope (Nikon, Ts2R model) at 200 times magnification. Oil-red-O stained with cells was extracted by treatment with 100% 2-propanol (Sigma Aldrich) for 30 minutes, and then absorbance was measured at 510 nm using a spectrometer (BioTeK).
도 1을 참조하면, 3T3-L1 세포에 황금추출물을 농도별로 처리하였을 때, 지방 생성이 점차 큰 폭으로 감소한 것을 확인할 수 있었다.Referring to FIG. 1 , it was confirmed that when 3T3-L1 cells were treated with gold extract by concentration, adipogenesis was gradually significantly reduced.
[준비예 2][Preparation Example 2]
아티초크잎을 이용하여 다음의 과정을 거쳐 아티초크잎추출물을 준비하였다. 구체적으로, 건조된 아티초크잎과 100% 에탄올을 1:10의 중량비율로 혼합한 후 상온에서 24 시간 동안 추출을 진행하여 추출물을 얻었다. 얻어진 추출물을 60 ℃로 가열하여 농축시킨 후에 400 mesh 폴리에틸렌(PE) 거름망으로 거른 후 열풍 건조하였고, 건조된 1 g의 추출물을 100% 에탄올 10 ml에 혼합하였다. 이후 75 % 에탄올로 20배 희석하여 아티초크잎추출물을 얻었다. Artichoke leaf extract was prepared through the following process using artichoke leaves. Specifically, dried artichoke leaves and 100% ethanol were mixed in a weight ratio of 1:10, followed by extraction at room temperature for 24 hours to obtain an extract. The resulting extract was concentrated by heating to 60 °C, filtered through a 400 mesh polyethylene (PE) sieve, and dried with hot air, and 1 g of the dried extract was mixed with 10 ml of 100% ethanol. Then, it was diluted 20 times with 75% ethanol to obtain an artichoke leaf extract.
[실험예 2] 아티초크잎추출물에 의한 지방세포 분화 억제 평가[Experimental Example 2] Evaluation of inhibition of adipocyte differentiation by artichoke leaf extract
아티초크잎추출물이 지방전구세포의 지방세포 분화에 영향을 주는지 확인하기 위해 생쥐 지방전구세포에 아티초크잎추출물을 농도별로 처리한 후 지방 생성을 측정하였으며, 그 결과를 도 2에 나타내었다. 이때, 측정 조건 및 과정은 실험예 1과 동일하게 적용하였다.To determine whether the artichoke leaf extract affects the differentiation of adipocytes into adipocytes, adipogenesis was measured after treatment with the artichoke leaf extract at different concentrations in mouse preadipocytes, and the results are shown in FIG. 2 . At this time, the measurement conditions and procedures were applied in the same manner as in Experimental Example 1.
도 2를 참조하면, 3T3-L1 세포에 아티초크잎추출물을 농도별로 처리하였을 때, 지방 생성이 점차 큰 폭으로 감소한 것을 확인할 수 있었다.Referring to FIG. 2 , when 3T3-L1 cells were treated with the artichoke leaf extract by concentration, it was confirmed that the adipogenesis was gradually significantly reduced.
[비교예 1][Comparative Example 1]
에탄올 0.2 %를 적용하였다. Ethanol 0.2% was applied.
[비교예 2][Comparative Example 2]
준비예 1의 황금추출물 25 중량부, 정제수 75 중량부가 혼합된 지방세포 분화 억제제를 적용하였다.An adipocyte differentiation inhibitor in which 25 parts by weight of the golden extract of Preparation Example 1 and 75 parts by weight of purified water were mixed was applied.
[실시예 1][Example 1]
준비예 1의 황금추출물 25 중량부, 준비예 2의 아티초크잎추출물 25 중량부, 정제수 50 중량부가 혼합된 지방세포 분화 억제제를 적용하였다.An adipocyte differentiation inhibitor in which 25 parts by weight of the golden extract of Preparation Example 1, 25 parts by weight of the artichoke leaf extract of Preparation Example 2, and 50 parts by weight of purified water were mixed was applied.
[실시예 2][Example 2]
준비예 1의 황금추출물 25 중량부, 준비예 2의 아티초크잎추출물 25 중량부, 카페인 2 중량부, 정제수 48 중량부가 혼합된 지방세포 분화 억제제를 적용하였다.An adipocyte differentiation inhibitor mixed with 25 parts by weight of the golden extract of Preparation Example 1, 25 parts by weight of the artichoke leaf extract of Preparation Example 2, 2 parts by weight of caffeine, and 48 parts by weight of purified water was applied.
[실시예 3][Example 3]
준비예 1의 황금추출물 25 중량부, 준비예 2의 아티초크잎추출물 25 중량부, 카페인 2 중량부, 테트라펩타이드(VHVV) 5 중량부, 정제수 43 중량부가 혼합된 지방세포 분화 억제제를 적용하였다.An adipocyte differentiation inhibitor mixed with 25 parts by weight of the golden extract of Preparation Example 1, 25 parts by weight of the artichoke leaf extract of Preparation Example 2, 2 parts by weight of caffeine, 5 parts by weight of tetrapeptide (VHVV), and 43 parts by weight of purified water was applied.
[실시예 4][Example 4]
준비예 1의 황금추출물 25 중량부, 준비예 2의 아티초크잎추출물 25 중량부, 카페인 2 중량부, 테트라펩타이드(VHVV) 5 중량부, 은행나무잎추출물 5 중량부, 정제수 38 중량부가 혼합된 지방세포 분화 억제제를 적용하였다. 25 parts by weight of golden extract of Preparation Example 1, 25 parts by weight of artichoke leaf extract of Preparation Example 2, 2 parts by weight of caffeine, 5 parts by weight of tetrapeptide (VHVV), 5 parts by weight of ginkgo leaf extract, 38 parts by weight of purified water Adipocyte differentiation inhibitor was applied.
[실험예 3] 지방세포 분화 억제 평가 1[Experimental Example 3] Adipocyte differentiation inhibition evaluation 1
지방세포의 분화와 지방 생성에 얼마만큼의 영향을 주는지 확인하기 위해 생쥐 지방전구세포인 3T3-L1 세포에 실시예 1, 실시예 2, 실시예 3, 실시예 4, 비교예 1 및 비교예 2의 시료를 각각 처리한 후 지방세포 분화를 유도하였으며, 그 결과를 도 3에 나타내었다. 이때, 측정 조건 및 과정은 실험예 1과 동일하게 적용하였다.In order to determine how much influence on adipocyte differentiation and adipogenesis, mouse preadipocytes, 3T3-L1 cells, were tested in Examples 1, 2, 3, 4, Comparative Example 1 and Comparative Example 2 Adipocyte differentiation was induced after each of the samples was treated, and the results are shown in FIG. 3 . At this time, the measurement conditions and procedures were applied in the same manner as in Experimental Example 1.
도 3를 참조하면, 본 발명에 따른 지방세포 분화 억제제인 실시예 1 내지 실시예 4를 3T3-L1 세포에 처리하였을 때, 지방 생성이 40 % 이하로 크게 감소된 반면에, 비교예 1 및 비교예 2의 경우는 지방생성이 크게 감소하지 않은 것을 확인할 수 있었다.Referring to FIG. 3 , when 3T3-L1 cells were treated with the adipocyte differentiation inhibitor of Examples 1 to 4 according to the present invention, adipogenesis was greatly reduced to 40% or less, whereas Comparative Example 1 and Comparative Example 4 In the case of Example 2, it was confirmed that the adipogenesis was not significantly reduced.
[실험예 4] 지방세포 분화 억제 평가 2[Experimental Example 4] Adipocyte differentiation inhibition evaluation 2
지방세포의 분화와 지방 생성에 얼마만큼의 영향을 주는지 확인하기 위해 생쥐 지방전구세포인 3T3-L1 세포에 실시예 3 및 비교예 1의 시료를 농도별로 각각 처리한 후 지방세포 분화를 유도하였으며, 그 결과를 도 4에 나타내었다. 이때, 측정 조건 및 과정은 실험예 1과 동일하게 적용하였다.To determine how much influence on adipocyte differentiation and adipogenesis, 3T3-L1 cells, which are mouse precursor cells, were treated with the samples of Example 3 and Comparative Example 1 by concentration, respectively, and then adipocyte differentiation was induced. The results are shown in FIG. 4 . At this time, the measurement conditions and procedures were applied in the same manner as in Experimental Example 1.
도 4를 참조하면, 본 발명에 따른 지방세포 분화 억제제인 실시예 3을 3T3-L1 세포에 처리하였을 때, 0.2% 농도에서 지방생성이 11.2%로 가장 낮은 것을 확인할 수 있었다.Referring to FIG. 4 , when 3T3-L1 cells were treated with Example 3, an adipocyte differentiation inhibitor according to the present invention, it was confirmed that the adipogenesis was the lowest at a concentration of 0.2% at 11.2%.
[실험예 5] 지방세포의 지방 분해 평가[Experimental Example 5] Evaluation of lipolysis in adipocytes
지방세포의 지방 분해 효능이 있는지 확인하기 위해 분화된 3T3-L1 지방세포에 실시예 3 및 비교예 1의 시료를 각각 처리한 후 48 시간 동안 배양하였다. 이후 광학현미경으로 관찰하였고 지방의 양은 실험예 1에 기재된 Oil-red-O 염색으로 측정하였으며 그 결과를 도 5에 나타내었다.In order to check whether the adipocytes have lipolytic efficacy, the samples of Example 3 and Comparative Example 1 were treated in differentiated 3T3-L1 adipocytes, respectively, and then cultured for 48 hours. Thereafter, it was observed with an optical microscope, and the amount of fat was measured by Oil-red-O staining described in Experimental Example 1, and the results are shown in FIG. 5 .
도 5을 참조하면, 본 발명에 따른 지방세포 분화 억제제인 실시예 3은 지방의 양이 48.2% 감소하여 지방 분해 효능이 우수한 것을 확인할 수 있었다.Referring to FIG. 5 , in Example 3, which is an adipocyte differentiation inhibitor according to the present invention, the amount of fat was reduced by 48.2%, and thus it was confirmed that the lipolysis efficacy was excellent.
[실험예 6] 지방 세포 특이적 유전자의 발현 억제 평가[Experimental Example 6] Evaluation of expression inhibition of adipocyte-specific genes
지방세포에서만 특이적으로 발현되는 유전자의 mRNA 생성에 영향을 주는지 확인하기 위해 생쥐 지방전구세포인 3T3-L1 세포에 실시예 3 및 비교예 1의 시료를 각각 처리하였다. 지방세포를 24시간 동안 분화 유도한 후 지방세포 특이적 유전자인 adipocyte protein 2(aP2), peroxisome proliferator-activated receptor gamma(PPAR-γ), adiponectin(ADIPOQ)의 mRNA양을 역전사중합효소연쇄반응 분석 (Reverse transcription polymerase chain reaction, RT-PCR)으로 확인하였으며, 그 결과를 도 6에 나타내었다. 이때, 측정 조건 및 과정은 다음과 같이 하였다. In order to check whether the mRNA production of genes specifically expressed only in adipocytes is affected, the samples of Example 3 and Comparative Example 1 were respectively treated in 3T3-L1 cells, which are mouse preadipocytes. After inducing differentiation of adipocytes for 24 hours, the mRNA levels of adipocyte protein 2 (aP2), peroxisome proliferator-activated receptor gamma (PPAR-γ), and adiponectin (ADIPOQ), which are adipocyte-specific genes, were analyzed by reverse transcriptase chain reaction ( Reverse transcription polymerase chain reaction, RT-PCR) was confirmed, and the results are shown in FIG. 6 . At this time, the measurement conditions and process were as follows.
RT-PCR assayRT-PCR assay
지방전구세포인 3T3-L1 세포를 6 well plate에 배양한 후, 지방세포로 분화 유도하였다. 이때, 실시예 3 및 비교예 1의 각 시료를 농도별로 48시간 동안 처리한 후 phosphate buffered saline(Hyclone사, PBS)로 세척 후 TRIzol Reagent(Invitrogen)를 각 세포에 1 mL 첨가한 후 1.5 ml 튜브로 옮겼다. Chloroform(Sigma aldrich사) 200 μL를 첨가하여 섞어준 후 실온에서 3분 동안 반응시킨 뒤에 4 ℃에서 13,000 rpm으로 10분 동안 원심분리하여 RNA 층을 분리시켰다. 이후 RNA를 취하여 동량의 isopropanol(Sigma aldrich사)을 첨가하여 10 분 동안 섞어준 다음 4 ℃에서 13,000 rpm으로 10분 동안 원심분리 하였다. 원심분리된 RNA를 에탄올로 2회 세척한 후 건조시킨 다음 뉴클레아제 프리 정제수로 녹이고 농도를 측정하였고, 추출한 RNA는 TOPscriptTM One-step RT PCR kit (Enzynomics)를 이용하여 cDNA를 합성하였다. RT-PCR을 위해 GAPDH와 PPAR-γ는 initial denaturation은 95 ℃에서 10분, denaturation은 95 ℃에서 30초, annealing은 55 ℃에서 60초, elongation은 72 ℃에서 60초의 조건으로 25 사이클을 진행하였고, aP2의 initial denaturation은 95 ℃에서 10분, denaturation은 95 ℃에서 30초, annealing은 57 ℃에서 60초, elongation은 72 ℃에서 60초의 조건으로 23 사이클을 진행하였고, ADIPOQ의 initial denaturation은 95 ℃에서 10분, denaturation은 95 ℃에서 30초, annealing은 57 ℃에서 60초, elongation은 72 ℃에서 60초의 조건으로 30 사이클을 진행하였다.After culturing 3T3-L1 cells, which are preadipocytes, in a 6 well plate, differentiation into adipocytes was induced. At this time, each sample of Example 3 and Comparative Example 1 was treated for 48 hours by concentration, washed with phosphate buffered saline (Hyclone, PBS), 1 mL of TRIzol Reagent (Invitrogen) was added to each cell, and then a 1.5 ml tube moved to After adding and mixing 200 μL of Chloroform (Sigma aldrich), the mixture was reacted at room temperature for 3 minutes, and then centrifuged at 13,000 rpm at 4 °C for 10 minutes to separate the RNA layer. After that, RNA was taken and the same amount of isopropanol (Sigma Aldrich) was added, mixed for 10 minutes, and then centrifuged at 4 °C at 13,000 rpm for 10 minutes. The centrifuged RNA was washed twice with ethanol, dried, dissolved in nuclease-free purified water, and the concentration was measured. The extracted RNA was cDNA synthesized using TOPscript TM One-step RT PCR kit (Enzynomics). For RT-PCR, 25 cycles of GAPDH and PPAR-γ were performed under the conditions of initial denaturation at 95 °C for 10 minutes, denaturation at 95 °C for 30 seconds, annealing at 55 °C for 60 seconds, and elongation at 72 °C for 60 seconds. , 23 cycles of aP2 initial denaturation at 95 °C for 10 min, denaturation at 95 °C for 30 sec, annealing at 57 °C for 60 sec, and elongation at 72 °C for 60 sec. 30 cycles were performed under the conditions of 10 min, denaturation at 95 °C for 30 sec, annealing at 57 °C for 60 sec, and elongation at 72 °C for 60 sec.
도 6을 참조하면, 본 발명에 따른 지방세포 분화 억제제인 실시예 3은 0.2% 농도에서 aP2, PPAR-r, ADIPOQ의 mRNA 발현양이 각각 15.6%, 3.6%, 12.7% 감소하여 지방 분화 억제 효능이 우수한 것을 확인할 수 있었다.Referring to FIG. 6 , in Example 3, which is an adipocyte differentiation inhibitor according to the present invention, the mRNA expression levels of aP2, PPAR-r, and ADIPOQ decreased by 15.6%, 3.6%, and 12.7%, respectively, at a concentration of 0.2%, thereby inhibiting adipocyte differentiation. This excellent thing could be confirmed.
[제조예 1][Production Example 1]
실시예 4의 지방세포 분화 억제제를 이용하여 화장료 조성물을 제조하였다. 구체적으로 1,2-헥산다이올 2.0 중량부, 판테놀 3.0 중량부, 1,3-부틸렌글라이콜 3.0 중량부, 글리세린 2.0 중량부를 정제수 72 중량부에 넣어 1,000 rpm으로 10분 동안 교반하여 수상 용해물을 제조하였다. 다음, 유상 용해물을 제조하기 위해 세틸에틸헥사노에이드(오일) 6.0 중량부, 카프릴릭/카프릭트리글리세라이드 6.0 중량부, 에틸헥실올리베이트 2.0 중량부, 세테아릴오리베이트 1.0 중량부를 80 ℃ 가온 용해하였고, 제조된 수상 용해물을 넣고 1,000 rpm으로 교반하여 유상 용해물을 제조하였다. 이후, 실시예 4의 지방세포 분화 억제제 2.4 중량부, 백미꽃추출물 1.0 중량부, 스폰지 스피큘 0.05 중량부를 추가로 투입하고 2,000 rpm으로 60 ℃에서 5분 동안 교반하는 과정을 거쳐 크림 제형의 화장료 조성물을 제조하였다.A cosmetic composition was prepared using the adipocyte differentiation inhibitor of Example 4. Specifically, 2.0 parts by weight of 1,2-hexanediol, 3.0 parts by weight of panthenol, 3.0 parts by weight of 1,3-butylene glycol, 2.0 parts by weight of glycerin purified water 72 It was put in parts by weight and stirred at 1,000 rpm for 10 minutes to prepare an aqueous solution. Next, in order to prepare an oily lysate, 6.0 parts by weight of cetylethylhexanoade (oil), 6.0 parts by weight of caprylic/capric triglyceride, 2.0 parts by weight of ethylhexylolivate, 1.0 parts by weight of cetearylorivate 80 Dissolved by heating at ℃, the prepared aqueous phase lysate was added and stirred at 1,000 rpm to prepare an oil phase lysate. Then, 2.4 parts by weight of the adipocyte differentiation inhibitor of Example 4, 1.0 parts by weight of white rice flower extract, and 0.05 parts by weight of sponge spicule were additionally added and stirred at 2,000 rpm at 60° C. for 5 minutes to obtain a creamy cosmetic composition. prepared.
[제조예 2][Production Example 2]
유상 용해물 제조 후, 회화나무열매추출물 0.5 중량부, 세룰라타벚나무꽃추출물 0.5 중량부를 더 투입하는 것을 제외하고는 제조예 1과 동일한 과정을 거쳐 크림 제형의 화장료 조성물을 제조하였다. 이때, 투입된 회화나무열매추출물과 세룰라타벚나무꽃추출물의 함량만큼 정제수의 함량을 줄여 조성을 조절하였다. After preparing the oily lysate, a cosmetic composition of a cream formulation was prepared through the same procedure as in Preparation Example 1, except that 0.5 parts by weight of the sycamore tree fruit extract and 0.5 parts by weight of the cerulata cherry blossom extract were further added. At this time, the composition was adjusted by reducing the content of purified water as much as the contents of the added Prunus oleifera fruit extract and Cerulata cherry blossom extract.
[실험예 6] 허벅지 셀룰라이트 개선 평가 [Experimental Example 6] Thigh cellulite improvement evaluation
제조예 1에서 얻어진 화장료 조성물이 지방 생성을 억제(방지)하는 효능(또는 지방을 분해하는 효능)이 있는지 확인하기 위해 세명대학교 화장품임상연구지원센터의 표준운영지침(SOP)에 근거하여 허벅지 셀룰라이트 감소 효과 여부를 평가하였으며, 그 결과를 도 7 및 도 8에 나타내었다. 구체적으로, 만 20~50세의 여성 시험 대상자 20명(평균연령 37.2)이 4주 동안 제조예 1의 화장료 조성물을 적당량 취하여 매일 오전, 오후 2회씩 대퇴부에 발랐다. 이후 대퇴부 사진 촬영 및 피부거칠기 분석을 위해 항온항습(22±2℃, RH40~60%) 조건에서 2주, 4주 후에 시험 대상자의 대퇴부를 고해상도 디지털 카메라(Canon EOS 50D)를 이용하여 화상사진을 촬영하였고, 피부 거칠기 평가는 3차원 영상 촬영장치인 PRIMOS(Phaseshift rapid in-vivo Measurement of skin)을 이용하여 화장료 조성물 사용 전과 사용 후 동일한 부위를 촬영한 후 제공된 소프트웨어 프로그램을 이용하여 거칠기 파라미터를 분석 비교하였다. 또한, 진피와 피하지방층 경계면 길이 측정은 초음파 촬영 장치인 DERMA SCAN® C Ver3. COMPACT(CORTEX TECHNOLOGY사)를 이용하여 화장료 조성물 사용 전과 사용 후 동일한 부위를 촬영한 후 제공된 소프트웨어 프로그램을 이용하여 분석하였다. In order to check whether the cosmetic composition obtained in Preparation Example 1 has the effect of inhibiting (preventing) the formation of fat (or the effect of decomposing fat), based on the standard operating guidelines (SOP) of the Cosmetics Clinical Research Support Center of Semyung University, thigh cellulite The reduction effect was evaluated, and the results are shown in FIGS. 7 and 8 . Specifically, 20 female test subjects aged 20-50 years (average age 37.2) took an appropriate amount of the cosmetic composition of Preparation Example 1 for 4 weeks and applied it to the thighs twice daily in the morning and afternoon. After 2 weeks and 4 weeks under constant temperature and humidity (22±2℃, RH40~60%) conditions for taking pictures of the thighs and analyzing skin roughness, images were taken of the subject's thighs using a high-resolution digital camera (Canon EOS 50D). In the evaluation of skin roughness, the same area was photographed before and after use of the cosmetic composition using PRIMOS (Phaseshift Rapid In-vivo Measurement of skin), a three-dimensional imaging device, and the roughness parameters were analyzed and compared using the provided software program. did In addition, the length of the interface between the dermis and the subcutaneous fat layer was measured using the ultrasound imaging device DERMA SCAN® C Ver3. Using COMPACT (CORTEX TECHNOLOGY), the same area was taken before and after use of the cosmetic composition, and then analyzed using the provided software program.
도 7 및 도 8을 참조하면, 본 발명에 따른 제조예 1의 화장료 조성물을 사용함에 따라 피부 거칠기 개선율이 10.1% 증가하였으며, 진피와 피하층 경계면 길이의 개선율이 20.4% 증가한 것을 확인할 수 있었다.7 and 8, by using the cosmetic composition of Preparation Example 1 according to the present invention, the improvement in skin roughness was increased by 10.1%, and it was confirmed that the improvement in the length of the interface between the dermis and the subcutaneous layer was increased by 20.4%.
Claims (9)
상기 황금추출물은 바이칼레인(Baicalein), 바이칼린(Baicalin), 디하이드로바이칼레인(Dihydrobaicalein), 오록실린 A(Oroxylin A), 디하이드로오록실린 A(Dihydrooroxylin A), 오고닌(Wogonin) 및 노르오고닌(Norwogonin)으로 이루어진 군에서 선택되는 1종 이상을 포함하는 것인 지방세포 분화 억제제.According to claim 1,
The golden extract is baicalein, baicalin, dihydrobaicalein, oroxylin A, dihydrooroxylin A, ogonin and norogo Adipocyte differentiation inhibitor comprising at least one selected from the group consisting of nin (Norwogonin).
상기 황금추출물과 상기 아티초크잎추출물의 혼합비율이 1:1 내지 5:1의 중량비인 것인 지방세포 분화 억제제.According to claim 1,
The adipocyte differentiation inhibitor that the mixing ratio of the golden extract and the artichoke leaf extract is a weight ratio of 1:1 to 5:1.
카페인, 펩타이드 및 은행나무잎추출물로 이루어진 군에서 선택되는 1종 이상을 더 포함하는 것인 지방세포 분화 억제제.According to claim 1,
Adipocyte differentiation inhibitor further comprising at least one selected from the group consisting of caffeine, peptides and ginkgo leaf extract.
상기 펩타이드는 Valine-Histidine-Valine-Valine(VHVV), Isoleucine-Leucine-Leucine(ILL) 및 Leucine-Leucine-Leucine(LLL)로 표시되는 펩타이드로 이루어진 군에서 선택되는 1종 이상인 것인 지방세포 분화 억제제.5. The method of claim 4,
The peptide is one or more selected from the group consisting of peptides represented by Valine-Histidine-Valine-Valine (VHVV), Isoleucine-Leucine-Leucine (ILL) and Leucine-Leucine-Leucine (LLL). .
스피큘을 포함하는 화장료 조성물.The adipocyte differentiation inhibitor according to any one of claims 1 to 5; and
A cosmetic composition comprising a spicule.
상기 스피큘이 가수분해 단백질 또는 친수성 물질로 코팅된 것인 화장료 조성물.7. The method of claim 6,
A cosmetic composition wherein the spicule is coated with a hydrolyzed protein or a hydrophilic material.
백미꽃추출물, 회화나무열매추출물 및 세룰라타벚나무꽃추출물로 이루어진 군에서 선택되는 1종 이상을 더 포함하는 것인 화장료 조성물.7. The method of claim 6,
A cosmetic composition that further comprises at least one selected from the group consisting of white rice flower extract, sycamore tree fruit extract, and cerulata cherry tree flower extract.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200068749 | 2020-06-08 | ||
| KR20200068749 | 2020-06-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20210152372A true KR20210152372A (en) | 2021-12-15 |
Family
ID=78845694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210035662A KR20210152372A (en) | 2020-06-08 | 2021-03-19 | Adipocyte differentiation inhibitor and composition comprising the same |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR20210152372A (en) |
| WO (1) | WO2021251603A1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170101081A (en) | 2016-02-25 | 2017-09-05 | 오명진 | Parenteral solution for diet containing lipolysis and celluite-improoving ingredient |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9144556B2 (en) * | 2011-01-21 | 2015-09-29 | Lion Corporation | Composition for promoting lipolysis |
| KR20130134976A (en) * | 2012-05-31 | 2013-12-10 | 주식회사 코스메카코리아 | A cosmetic composition for whitening skin containing cynanchum atratum extracts |
| KR101757841B1 (en) * | 2014-11-12 | 2017-07-14 | 한국생명공학연구원 | Composition for inhibiting obesity comprising complex salt of baicalin and zinc |
| KR101515865B1 (en) * | 2015-03-02 | 2015-05-04 | 박성율 | A step 6 method for improving skin condition using composition comprising red-wilfordi root and black-ginseng fermentation extract haved skin whitening function |
| KR102074214B1 (en) * | 2019-09-06 | 2020-02-06 | 주식회사 에이치앤비나인 | A structure for accelerating transdermal absorption, a manufacturing method the same, and a cosmetics composition comprising the same |
-
2021
- 2021-03-19 KR KR1020210035662A patent/KR20210152372A/en not_active Application Discontinuation
- 2021-04-06 WO PCT/KR2021/004242 patent/WO2021251603A1/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170101081A (en) | 2016-02-25 | 2017-09-05 | 오명진 | Parenteral solution for diet containing lipolysis and celluite-improoving ingredient |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021251603A1 (en) | 2021-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6929836B2 (en) | Composition for skin improvement and hair loss prevention containing extracellular endoplasmic reticulum derived from plant juice | |
| JP5628797B2 (en) | Skin external preparation composition containing ginseng flower or ginseng seed extract | |
| JP6514298B2 (en) | Composition for promoting circulation, preventing blood vessel aging and treating ischemic heart disease, comprising a ginseng berry extract | |
| KR101550917B1 (en) | Composition for applying to skin externally containing extract from seeds of ginseng | |
| KR101438367B1 (en) | Composition of skin external application containing ginseng fruit extracts | |
| AU2017345384A1 (en) | Extract of Anigozanthos flavidus for cosmetic use | |
| KR101059471B1 (en) | Cosmetic composition for skin aging | |
| KR101387308B1 (en) | Skin whitening composition by using of dendropanax morbifera ferment extract | |
| WO2009069906A1 (en) | Composition for skin external application containing complex of herbal extracts | |
| JPWO2004085429A1 (en) | Composition for promoting type I collagen and / or elastin production | |
| WO1999062481A1 (en) | Cosmetic treatment method for fighting against skin ageing effects | |
| US20200254044A1 (en) | Composition comprising plant-derived extracellular vesicles | |
| CN111053716A (en) | Application of Fuzhuan tea extract in preparation of skin conditioning product | |
| KR20070092052A (en) | A composition for promoting hair growth | |
| KR20090129928A (en) | Composition for applying to skin externally containing extract from flower of ginseng | |
| TW202102242A (en) | Fermentation product ofphyllanthus emblica extract and preparation and use of the same | |
| EP4169502A1 (en) | Cosmetic and dermatological use of rubus fruticosus fruit extract | |
| KR20130036984A (en) | Cosmetic composition for inhibiting hair loss and enhanching hair growth | |
| KR20210152372A (en) | Adipocyte differentiation inhibitor and composition comprising the same | |
| KR20140089305A (en) | Composition for improving skin whitening or skin wrinkle comprising extracts of Quercus salicina Blume | |
| MX2014009188A (en) | Use of starfruit extract as a cpt-1 modulator and compositions thereof. | |
| CN112638357A (en) | Composition for promoting differentiation or proliferation of human adipose-derived stem cells | |
| CN113631227A (en) | Antiaging agent, antioxidant, antiinflammatory agent, whitening agent, and cosmetic | |
| CN118021632A (en) | Composition for promoting differentiation or proliferation of human adipose-derived stem cells | |
| KR20200023163A (en) | A composition for promoting the differentiation of human adipose derived stem cell |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal |